Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers

The standard treatment for advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is the triple combination of pertuzumab, trastuzumab and docetaxel, but some patients cannot tolerate taxane. To explore a non-taxane triple therapy, we conducted a feasibility study of pertuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tono, Yasutaka, Ishihara, Mikiya, Miyahara, Yoshihiro, Tamaru, Satoshi, Oda, Hiroyasu, Yamashita, Yoshiki, Tawara, Isao, Ikeda, Hiroaki, Shiku, Hiroshi, Mizuno, Toshiro, Katayama, Naoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871086/
https://www.ncbi.nlm.nih.gov/pubmed/29599915
http://dx.doi.org/10.18632/oncotarget.24504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871086/
https://www.ncbi.nlm.nih.gov/pubmed/29599915
http://dx.doi.org/10.18632/oncotarget.24504

Ejemplares similares